CAR-T cell therapy is already a potent treatment for certain cancers. Now, a small study is showing early promise for managing HIV. https://t.co/kT0ODPkzqw
Nigeria Targets Breakthrough In Gene Therapy Through Global Health Partnerships
The Federal Government has announced plans to adopt Chimeric Antigen Receptor (CAR) T-cell therapy and other gene-based technologies to advance medical treatment - a move aimed at strengthening Nigeria's healthcare system and expanding access to cutting-edge therapies. @SalakoIziaq disclosed this during an interactive session on an emerging partnership with @caring_cross, a collaboration initiated by @NIPRD2
#HealthInnovations
#MedicinesSecurity
🎉Este ano, a Fiocruz celebra 126 anos de ciência e saúde pela vida!
Nos dias 25, 26 e 27 de maio, o Campus Manguinhos recebe uma programação especial em comemoração ao aniversário da instituição.
📍 Praça Pasteur – Campus Manguinhos
📱Transmissão pelo Canal da Fiocruz no YouTube
Reserve sua agenda e participe desta celebração!🧡
#Fiocruz #Fiocruz126anos
Nigeria is stepping into the future of medicine
“It was my honor to be hosted by Hon. Minister Dr. Iziaq Adekunle Salako. Let us work together to bring affordable and accessible cellular and gene therapies to Nigeria.” —Boro Dropulić
https://t.co/WaPwtommOO
#HealthEquity#Nigeria
FEDERAL MINISTRY OF HEALTH AND SOCIAL WELFARE
Press Release
NIGERIA TARGETS BREAKTHROUGH THERAPIES IN NEW PUSH FOR MEDICINE SECURITY
Abuja, Nigeria| 05 May 2026 —The Federal Government has launched a new push to expand access to advanced medical treatments in Nigeria, positioning gene therapy and other frontier technologies as central to the country’s long-term medicine security strategy.
This direction was outlined during a high-level engagement in Abuja between the Federal Ministry of Health and Social Welfare, global non-profit Caring Cross, and key research and industry partners.
The Honourable Minister of State for Health and Social Welfare, Dr. Iziaq Adekunle Salako, said Nigeria is moving deliberately to close the gap between scientific discovery and patient access, particularly in areas where life-saving treatments remain out of reach for many.
He emphasised that the President Tinubu led administration is prioritising health innovation as part of its broader efforts to strengthen national resilience, drive local production, and reduce dependence on external supply chains.
At the centre of the discussions was the potential introduction of Chimeric Antigen Receptor (CAR) T-cell therapy, an advanced form of treatment showing promise in managing conditions such as sickle cell disease and certain blood cancers.
While widely explored in other regions, CAR-T therapy remains largely inaccessible across Africa. The Minister noted that changing this reality requires deliberate investment in research, partnerships, and the systems needed to translate innovation into real-world care.
“Our goal is clear, to ensure that breakthroughs in science are not distant concepts, but accessible solutions for Nigerians,” he said.
The engagement also highlighted Nigeria’s ongoing pharmaceutical and research reforms, anchored by the Presidential Initiative on Vaccine and Biologicals Production (PVAC), aimed at strengthening local manufacturing, expanding vaccine and biological production, and building a more coordinated innovation ecosystem.
In her remarks, the Permanent Secretary, Daju Kachollom S. mni, represented by the Director, Health Planning, Research & Statistics, described the meeting as a convergence of science, policy, and opportunity.
Daju noted that emerging fields such as gene therapy and regenerative medicine are redefining modern healthcare and present an important opportunity for Nigeria to leapfrog traditional limitations in access to treatment. “Partnerships like this are critical to ensuring that innovation translates into sustainable improvements in our health system,” she said.
Caring Cross Chief Executive Officer, Dr. Boro Dropulic, highlighted the organisation’s work in expanding access to cellular and gene therapies globally, with a focus on affordability and scalability in low- and middle-income countries. He pointed to the rising burden of genetic and blood-related diseases in Nigeria, particularly among children, as a compelling case for accelerating access to next-generation treatments.
Also contributing, the Director-General of the National Institute of Pharmaceutical Research and Development, Dr. Obi Adigwe, outlined steps already taken to position Nigeria as a leader in pharmaceutical research and development on the continent. These include securing major international research funding, strengthening regional collaboration, and advancing infrastructure for local production of active pharmaceutical ingredients.
He noted that Nigeria is increasingly adopting a coordinated, multi-sector approach that brings together government institutions, research bodies, and global partners to drive innovation at scale.
The meeting marks an early but significant step in Nigeria’s ambition to move from being a consumer of advanced therapies to an active participant in their development, adaptation, and delivery.
Ado Bako Assistant Director, Information & Public Relations
BioCurie will receive up to $9.3M from ARPA-H to build an AI-powered platform for scalable, data-driven gene therapy manufacturing. We’re honored to collaborate, to accelerate innovation and expand access.
Learn more: https://t.co/m7O05HD2PF
#AdvancedTherapies#BioCurie#ARPAH
We’re excited to announce a new collaboration in Croatia supporting CAR-T cell manufacturing at the Sisters of Mercy University Hospital GMP facility, in partnership with the Zora Foundation.
#GlobalHealth#CARTcellTherapy#HealthEquity#Croatia
Caring Cross announces a new partnership with Amrita Research Center Delhi & Amrita Vishwa Vidyapeetham to bring affordable cell & gene therapies to underserved communities across India — a major step toward true health equity.
https://t.co/IpVGQn39P8
#CellTherapy#HealthEquity
Biotech Webinar – June 6 @ 3PM ET
T Cell Selection: A Critical Step in the CAR-T Process
How do we isolate T cells—and why does it matter for access?
🔗 Register: https://t.co/aqCj39wR2A
#CART#CellTherapy#Biotech#HealthEquity
Health is a basic human right.
Everyone should be able to access quality health services whenever & wherever they need them, 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗱𝗶𝘀𝘁𝗶𝗻𝗰𝘁𝗶𝗼𝗻 of any kind.
See how you can help achieve #HealthForAll: https://t.co/YeL0ZRLgfs
Our joint meeting with @parkerici addressed industry challenges in #celltherapy manufacturing and highlighted key solutions: regulatory flexibility, cross-sector collaboration, and alternative business models.
Watch the full meeting: https://t.co/efiNLr1H3g
#CGTFriends
"What governments and people don't realise is that sometimes the collective interest - the international interest - is also the national interest." — Kofi Annan (1938-2018)
#MondayMotivation
Thank you to everyone who joined today’s “Unlocking Next-Gen Therapies” event! Grateful to @CancerResrch & @ParkerICI for organizing, and to the incredible panelists for an insightful discussion.
Missed it? https://t.co/eg6GIpuHqZ
#CellTherapy#HealthEquity#AccessForAll